Word

VERZENIO VISION

Status

Dead

Status Code

601

Status Date

Tuesday, November 7, 2023

Serial Number

98227410

Mark Type

3000

Filing Date

Tuesday, October 17, 2023

Abandoned Date

Monday, November 6, 2023

Trademark Owner History

Eli Lilly and Company

Classifications

5 Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

The mark consists of the stylized wording "VERZENIO VISION" and design. The design consists of a horizontal line before and after a triangular shield-like shape formed with lines that intertwine positioned above the letter "Z" in the term "VERZENIO" which appears in a large font. The term "VISION" appears in a small font and is centered below the term "VERZENIO" with a horizontal line before and after the term "VISION".
Color is not claimed as a feature of the mark.

Trademark Events

Nov 7, 2023

Abandonment Notice E-Mailed - Express Abandonment

Nov 6, 2023

Teas Express Abandonment Received

Nov 7, 2023

Abandonment Notice Mailed - Express Abandonment

Nov 7, 2023

Abandonment - Express Mailed

Oct 25, 2023

Notice Of Design Search Code E-Mailed

Oct 24, 2023

New Application Office Supplied Data Entered

Oct 20, 2023

New Application Entered